Switch theme
Sign up to access all valuation multiples
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
2008
649
LTM Revenue $615M
LTM EBITDA -$111M
$8.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Blueprint Medicines has a last 12-month revenue (LTM) of $615M and a last 12-month EBITDA of -$111M.
In the most recent fiscal year, Blueprint Medicines achieved revenue of $509M and an EBITDA of $19.2M.
Blueprint Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Blueprint Medicines valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $615M | XXX | $509M | XXX | XXX | XXX |
| Gross Profit | $589M | XXX | $489M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | -$111M | XXX | $19.2M | XXX | XXX | XXX |
| EBITDA Margin | -18% | XXX | 4% | XXX | XXX | XXX |
| EBIT | -$139M | XXX | -$212M | XXX | XXX | XXX |
| EBIT Margin | -23% | XXX | -42% | XXX | XXX | XXX |
| Net Profit | -$53.3M | XXX | -$67.1M | XXX | XXX | XXX |
| Net Margin | -9% | XXX | -13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $285M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Blueprint Medicines's stock price is $128.
Blueprint Medicines has current market cap of $8.3B, and EV of $8.2B.
See Blueprint Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.2B | $8.3B | XXX | XXX | XXX | XXX | $-0.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Blueprint Medicines has market cap of $8.3B and EV of $8.2B.
Blueprint Medicines's trades at 16.1x EV/Revenue multiple, and 425.2x EV/EBITDA.
Equity research analysts estimate Blueprint Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Blueprint Medicines has a P/E ratio of -155.6x.
See valuation multiples for Blueprint Medicines and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.3B | XXX | $8.3B | XXX | XXX | XXX |
| EV (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
| EV/Revenue | 13.3x | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBITDA | -73.9x | XXX | 425.2x | XXX | XXX | XXX |
| EV/EBIT | -58.7x | XXX | -38.6x | XXX | XXX | XXX |
| EV/Gross Profit | 13.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -155.6x | XXX | -123.5x | XXX | XXX | XXX |
| EV/FCF | -62.7x | XXX | -41.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBlueprint Medicines's last 12 month revenue growth is 36%
Blueprint Medicines's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.1M for the same period.
Blueprint Medicines's rule of 40 is -152% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Blueprint Medicines's rule of X is 72% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Blueprint Medicines and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Margin | -18% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | -139% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -152% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 72% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 67% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 138% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Blueprint Medicines acquired XXX companies to date.
Last acquisition by Blueprint Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . Blueprint Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Blueprint Medicines founded? | Blueprint Medicines was founded in 2008. |
| Where is Blueprint Medicines headquartered? | Blueprint Medicines is headquartered in United States of America. |
| How many employees does Blueprint Medicines have? | As of today, Blueprint Medicines has 649 employees. |
| Who is the CEO of Blueprint Medicines? | Blueprint Medicines's CEO is Ms. Kathryn Haviland. |
| Is Blueprint Medicines publicy listed? | Yes, Blueprint Medicines is a public company listed on NAS. |
| What is the stock symbol of Blueprint Medicines? | Blueprint Medicines trades under BPMC ticker. |
| When did Blueprint Medicines go public? | Blueprint Medicines went public in 2015. |
| Who are competitors of Blueprint Medicines? | Similar companies to Blueprint Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Blueprint Medicines? | Blueprint Medicines's current market cap is $8.3B |
| What is the current revenue of Blueprint Medicines? | Blueprint Medicines's last 12 months revenue is $615M. |
| What is the current revenue growth of Blueprint Medicines? | Blueprint Medicines revenue growth (NTM/LTM) is 36%. |
| What is the current EV/Revenue multiple of Blueprint Medicines? | Current revenue multiple of Blueprint Medicines is 13.3x. |
| Is Blueprint Medicines profitable? | Yes, Blueprint Medicines is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Blueprint Medicines? | Blueprint Medicines's last 12 months EBITDA is -$111M. |
| What is Blueprint Medicines's EBITDA margin? | Blueprint Medicines's last 12 months EBITDA margin is -18%. |
| What is the current EV/EBITDA multiple of Blueprint Medicines? | Current EBITDA multiple of Blueprint Medicines is -73.9x. |
| What is the current FCF of Blueprint Medicines? | Blueprint Medicines's last 12 months FCF is -$130M. |
| What is Blueprint Medicines's FCF margin? | Blueprint Medicines's last 12 months FCF margin is -21%. |
| What is the current EV/FCF multiple of Blueprint Medicines? | Current FCF multiple of Blueprint Medicines is -62.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
